Entinostat (MS-275)

Catalog No.S1053 Synonyms: SNDX-275

Entinostat (MS-275) Chemical Structure

Molecular Weight(MW): 376.41

Entinostat (MS-275) strongly inhibits HDAC1 and HDAC3 with IC50 of 0.51 μM and 1.7 μM in cell-free assays, compared with HDACs 4, 6, 8, and 10. Phase 3.

Size Price Stock Quantity  
In DMSO USD 91 In stock
USD 70 In stock
USD 150 In stock
USD 270 In stock
USD 770 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 61 Publications

14 Customer Reviews

  • (A) U87 cells were cultured in the presence of DMSO, 1 uM MS-275 alone, 100 ng/ml IFN-λ1 alone, or both for the course of 4 d. Cell numbers were manually determined by hemacytometer counting at the indicated time points. (B, F) Cell proliferation of U87 cells or U87 spheroids in 3D culture with indicated treatment were performed using the WST-1 assay, which measures active cellular metabolism. (C) U87 spheroid formation in 3D culture was photographed at day 14 in culture (representative images are shown; 200x magnification). (D-E) Quantification of the relative sizes and numbers of U87 spheroids in (C). (G) Cell cycle analysis was performed in U87 cells with indicated treatment using propidium iodide staining. Numbers in the histogram show fractions (percent) of sub-G1, N, 2N, and polyploidy from left to right. (H) U87 cells with indicated treatment were stained with Annexin V-FITC and 7-AAD. Numbers indicate the percentage of FITC-positive cells (upper left quadrant). FITC, fluorescein isothiocyanate; 7-AAD, 7-Aminoactinomycin. In all panels, data represent the mean and SEM of at least three experiments.

    PLoS Biol 2014 12, e1001758. Entinostat (MS-275) purchased from Selleck.

    Numerous APC (+) oligodendrocytes (middle upper panel) with ellipsoid nuclei labeled with Sytox (left upper panel) were observed in 8 week old Thy-1 mitoCFP control MONs. NF-200 (+) neurofilaments extended along the MON as linear individual fibers (right upper panel). A period of OGD (60 min) caused a significant loss of APC (+) oligodendrocytes, a gain in the appearance of pyknotic nuclei (dense, brighter nuclei, white arrows, OGD panel), and loss of NF-200 (+) axon structures, which were, replaced with axonal head and bulb formation (white asterisks). Pretreatment with SAHA (1uM) or MS-275 (1uM) effectively preserved APC (+) oligodendrocytes, together with numerous linear individual NF-200 (+) axons. Note fewer pyknotic nuclei (white arrows, SAHA and MS-275 panels) after OGD in MONs treated with SAHA or MS-275.

    J Neurosci 2011 31, 3990-9. Entinostat (MS-275) purchased from Selleck.

  • Inhibition of HDAC1-mediated DNMT1 deacetylation promotes DNMT1 proteasomal degradation. (A) Knockout of HAUSP potentiates HDAC inhibitor (HDACi)-induced DNMT1 degradation. Parental or HAUSP KO DLD1 cells were treated or not with 5 μM HDACi MS-275 for 72 hours and cell lysates were blotted with the indicated antibodies. (B) HDAC inhibition induces DNMT1 ubiquitination. HAUSP WT or KO cells were treated with or without HDACi for 24 hours and MG132 for 12 hours before being harvested to make cell lysates. DNMT1 immunoprecipitates were blotted with an antibody against ubiquitin. Because the abundance of DNMT1 in the HAUSP KO cells is lower than in WT cells, more KO cells were used than WT cells to obtain equal amounts of precipitated DNMT1 proteins. (C) DNMT1 is acetylated after HDACi treatment. DNMT1 immunoprecipitates from cells treated with HDACi were blotted with an antibody against acetylated lysine (Ac-K). (D) A DNMT1 acetylation site mutant is resistant to HDACi-induced degradation. HEK 293 cells were transfected with WT DNMT1 or a DNMT1 mutant lacking four known acetylation sites (K173R, K1113R, K115R, and K117R) and treated with MS-275 for 48 hours and with CHX for 24 hours. Cell lysates were blotted with the indicated antibodies. (E) Knockdown of HDAC1 decreases the abundance of DNMT1. RKO cells were treated with the indicated concentration of doxycycline (Dox) for 48 hours to induce expression of an shRNA directed against HDAC1. Western blots were performed with the indicated antibodies. (F) Knockdown of HDAC1 leads to increased acetylation of DNMT1. RKO cells expressing an inducible HDAC1 shRNA were treated with or without Dox (4 mg/ml) for 36 hours and then with MG132 for 12 hours. DNMT1 immunoprecipitates were blotted with an antibody against Ac-K. Cell lysates were also blotted with antibodies against HDAC1 and b-actin.

     

     

    Sci Signal 2010 3, ra80. Entinostat (MS-275) purchased from Selleck.

    The E3 ligase UHRF1 ubiquitinates DNMT1. (A) HDAC inhibition enhances DNMT1 interaction with UHRF1. HEK 293 cells were transfected with plasmids expressing Myc-DNMT1 and Flag-UHRF1 and treated with or without MS-275 for 24 hours. Myc-DNMT1 immunoprecipitates were blotted with the indicated antibodies. (B and C) HDAC inhibition enhances the interaction of endogenous DNMT1 and UHRF1. Cells were treated with or without MS-275 and UHRF1 (B) or DNMT1 (C) immunoprecipitates were blotted with the indicated antibodies. (D) UHRF1 ubiquitinates DNMT1. HEK 293 cells were transfected with the indicated plasmids. Antibodies against Myc immunoprecipitates were blotted with antibody against HA to detect ubiquitinated DNMT1. Myc-DNMT1D, DNMT1 mutant lacking the HAUSP-interacting domain. UHRF1DRING, UHRF1 with a RING domain deletion. (E) Knockdown of UHRF1 blocks HDACi-induced DNMT1 degradation. HEK 293 cells were transfected with control siRNA or siRNAs against UHRF1 and treated with or without MS-275. Western blotting was performed with the indicated antibodies. (F) Overexpression of UHRF1 leads to degradation of a DNMT1 mutant lacking the HAUSP-interacting domain (DNMT1D). Full-length DNMT1 or DNMT1D was cotransfected into HEK 293 cells with the indicated expression vectors. Cell lysates were blotted with the indicated antibodies. (G) DNMT1, HAUSP, UHRF1, HDAC1, and PCNA associate with Tip60. Flag-tagged Tip60 immunoprecipitates were blotted with the indicated antibodies.

     

     

    Sci Signal 2010 3, ra80. Entinostat (MS-275) purchased from Selleck.

  • HAUSP KO cells are more sensitive to HDACi-induced apoptosis.(A) HDAC inhibition induces apoptosis in HAUSP KO cells.HAUSP WT or KO cells were treated with or without MS-275 at the indicated concentration for 72 hours, then fixed and stained with propidium iodide. Flow cytometric analyses were used to profile sub-G1, G1, and G2-M cell populations. Apoptotic cells were quantified after the indicated clones were treated with either 5 or 10 μM MS-275. The means and SDs of three independent experiments were plotted (*P<0.001, t test). (B) HDAC inhibition induces apoptosis in HAUSP KO cells but leads to G2-M arrest in WT cells.Cell cycle profiles of HAUSP WT or KOcells that were treated or not with 5 μM MS-275. (C)HDAC inhibition increases the abundance of apoptotic cell markers. The indicated cells were treated with or without MS-275 for 72 hours.Cell lysates were blotted with antibodies against cleaved caspase 3 and β-actin. (D) Ectopic overexpression of DNMT1 in HAUSP KO cells suppresses apoptosis. HAUSP KO clones or HAUSP KO cells inducibly

    overexpressingDNMT1 were treatedwith 10 μM MS-275. Apoptotic cell populations were quantified by fluorescence-activated cell sorting (FACS) analyses (*P < 0.001, t test). Cell lysates from these cells were blotted with the indicated antibodies. (E) HDAC inhibition arrests the growth of HAUSP KO cells. DLD1, HAUSP KO, and KO cells ectopically expressing HAUSP were treated with the indicated concentration of MS-275 for 4 days. Cell numbers were determined and data from eight replicates were plotted (**P <0.001, t test). (FandG) HDACi inhibits tumor xenograft formation ofHAUSP KOcells.Athymic nudemice (five in each group)were injectedsubcutaneously and bilaterallywith cells of the indicated genotypes. Mice were treated with or without MS-275 at 15mg/kg for 4 weeks. Tumors were harvested and photographed (F). Tumor sizes of the indicated groupsweremeasuredweekly and theaveragevolumes at each timepoint were plotted (G).MANOVA analyses were performed to determine whether there was an overall difference of the tumor sizes, as well as whether there was a difference in development over time of tumor sizes between the two groups (P < 0.0001).
     

     

    Sci Signal 2010 3, ra80. Entinostat (MS-275) purchased from Selleck.

    Notch1ICD, Notch2ICD, and Notch3ICD were transduced into human aortic SMCs, which were then treated with HDAC inhibitors TSA or MS-275 or with vehicle DMSO (con). The top 2 rows are different exposures of the same blot to detect the epitope tags on the N ICD constructs. Longer (top row) and shorter ( second row) exposures are shown because t he level of N2ICD expression was lower than that of N1ICD and N3ICD. SMC markers were analyzed and were similarly induced by activation of each Notch r eceptor. Both TSA and MS-275 significantly suppressed the induction of SMC proteins by Notch activation.

    J Am Heart Assoc 2012 1, e000901. Entinostat (MS-275) purchased from Selleck.

  • LSD1 and HDAC inhibitors exhibit synergistic growth inhibition. Cells were simultaneously treated with pargyline or HDAC inhibitors for 48 h.

     

     

    Breast Cancer Res Treat 2012 131, 777-789. Entinostat (MS-275) purchased from Selleck.

    Inhibition of LSD1 activity by HDAC inhibitors. a MDA-MB-231 and MDA-MB-468 cells were exposed to indicated HDAC inhibitors for 24 h.

     

     

    Exp Dermatol 2010 19, 1096-1102. Entinostat (MS-275) purchased from Selleck.

  • Histone acetylation in the spinal cord after HDACI treatment. Histone acetylation in the lumbar spinal cord of mice receiving i.t. SAHA (25 μg) or MS-275 (0.5 μg) for 30 min was analyzed by immunoblot (A, B) and immunofluorescent histochemistry (C) for antigens indicated. Animals receiving i.t. saline were used as control. Images of the H3K9/18ac signals in the left half of the lumbar spinal cord are shown in the first row in C. Immunosignals of indicated antigens in the superficial dorsal horn are presented in the rest rows in C.

    Mol Pain 2010 6, 51. Entinostat (MS-275) purchased from Selleck.

    B. Confluent quiescent foreskin fibroblasts were treated with HDAC1 inhibitor or vehicle for 24 hours. Type I procollagen protein levels in whole cell lysates were determined by immunoblotting. A representative result of three independent experiments is shown. The band density was evaluated by densitometry. C. Under the same conditions, mRNA levels of the α1(I) collagen (COL1A1) gene were determined using reverse transcription quantitative real-time PCR. The graph represents -fold change in COL1A1 mRNA levels in comparison to unstimulated controls, which were arbitrarily set at 100. The mean and SD from three separate experiments are shown. * p<0.05 versus control cells treated with vehicle.

    PLoS One 2013 8, e74930. Entinostat (MS-275) purchased from Selleck.

  •  

    HDAC inhibition increases SMN-luciferase reporter mRNA levels. qRT-PCR was used to measure increases of SMN-luciferase mRNA following treatment with HDAC inhibitors. Fold increase of mRNA was normalized to GAPDH.

    Biochem Bioph Res Co 2010 414, 25-30. Entinostat (MS-275) purchased from Selleck.

    HCT116 p53 null cells were treated with different HDACIs (1 μM TSA, 5 μM M344, 1 μM MS-275, 5 mM But, 10 mM VPA) for 24 h, and their expression of GRP78, PERK-eIF2α axis and ATF4, ATF3, CHOP and DR5 proteins.

    Biochem Biophys Res Commun 2014 10.1016/j.bbrc.2014.01.184. Entinostat (MS-275) purchased from Selleck.

  • HCT116 p53 null cells were treated with different HDACIs (1 μM TSA, 5 μM M344, 1 μM MS-275, 5 mM But, 10 mM VPA) for 24 h. ATF4, ATF3, CHOP and DR5 proteins were measured by Western blot.

    Biochem Biophys Res Commun 2014 10.1016/j.bbrc.2014.01.184. Entinostat (MS-275) purchased from Selleck.

    Western blot analysis of Acetyl-H3 and H3. 0-20μM MS-275 was added.

     

     

    2011 Dr. Zhang of Tianjin Medical University. Entinostat (MS-275) purchased from Selleck.

Purity & Quality Control

Choose Selective HDAC Inhibitors

Biological Activity

Description Entinostat (MS-275) strongly inhibits HDAC1 and HDAC3 with IC50 of 0.51 μM and 1.7 μM in cell-free assays, compared with HDACs 4, 6, 8, and 10. Phase 3.
Targets
HDAC1 [2]
(Cell-free assay)
HDAC3 [2]
(Cell-free assay)
0.51 μM 1.7 μM
In vitro

MS-275 shows inhibitory to HDACs by 2'-amino group. MS-275 induces accumulation of p21WAF1/CIP1 and gelsolin in K562 cell. MS-275 could reduce S-phase cells and induce G1-phase cells in A2780 cell. MS-275 inhibits the proliferation of human tumor cell lines including A2780, Calu-3, HL-60, K562, St-4, HT-29, KB-3-1, Capan-1, 4-1St and HCT-15 with IC50 from 41.5 nM to 4.71 μM, which due to HAD-inhibition. [1] MS-275 is not sensitive to other HDACs (4, 6, 8 and 10) with IC50 about/above 100 μM. [2] MS-275 shows great inhibition to human leukemia and lymphoma cells, including U937, HL-60, K562, and Jurkat. MS-275 also decreases expression of cyclin D1 and the antiapoptotic proteins Mcl-1 and XIAP. [3]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
SCC-3 M4S5b2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2nubGlEPTB;MD6wOlEh|ryP Mlz3V2FPT0WU
ALL-PO MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnewTWM2OD1yLkC2N|U2KM7:TR?= MXzTRW5ITVJ?
697 NGDqeZlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{LzWWlEPTB;MD6wPVk4PiEQvF2= NHrCXJNUSU6JRWK=
NCI-H748 NEm0c5VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVfGV2dCUUN3ME2wMlExOzN2IN88US=> NWPsd|BIW0GQR1XS
NKM-1 NUTOVoJvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHjZXVhKSzVyPUCuNVA6OTJizszN M{nwVnNCVkeHUh?=
ES1 M4Gwbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3\DV2lEPTB;MD6xNVI2PSEQvF2= NXm5eZhHW0GQR1XS
NCI-H1963 M{LWe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3\GZ2lEPTB;MD6xNVU4QSEQvF2= NULGdmdLW0GQR1XS
NCI-H1417 NE\K[2hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkPqTWM2OD1yLkGyPVc1KM7:TR?= NEfwXXJUSU6JRWK=
NEC8 NIHOeVFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIqxVm5KSzVyPUCuNVM2OjdizszN NUPCNFJpW0GQR1XS
CRO-AP2 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2\0R2lEPTB;MD6xOlg5QSEQvF2= NVj2OWJbW0GQR1XS
A3-KAW MmTXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3rG[mlEPTB;MD6xO|YzPyEQvF2= MkDxV2FPT0WU
SF539 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4LVbGlEPTB;MD6xPVU6OyEQvF2= MluzV2FPT0WU
NOS-1 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmPlTWM2OD1yLkG5OlE6KM7:TR?= NV3nVWlOW0GQR1XS
NTERA-S-cl-D1 M1jNdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MU\JR|UxRTBwMkCxNVMh|ryP MWDTRW5ITVJ?
COR-L88 M{nwW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYHJR|UxRTBwMkK5OVkh|ryP NHnW[YlUSU6JRWK=
EM-2 M1PCcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEP1VI9KSzVyPUCuNlQxPzlizszN MV7TRW5ITVJ?
KARPAS-45 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWHJR|UxRTBwMke4N|Mh|ryP NF3PVo5USU6JRWK=
DSH1 M2C0Z2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF;sWotKSzVyPUCuNlg4ODhizszN MXHTRW5ITVJ?
HT-144 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWDBPGhGUUN3ME2wMlMxOjV4IN88US=> NXfEdJVnW0GQR1XS
ATN-1 NFXjbHhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4fhdGlEPTB;MD6zNFU4PiEQvF2= NXvhPJc5W0GQR1XS
HEL M{D2PWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGnHO3lKSzVyPUCuN|E{PDhizszN NGG4XXRUSU6JRWK=
NB12 Mof6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEmxPZVKSzVyPUCuN|E4PTZizszN M17uSXNCVkeHUh?=
LU-139 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXWwdm4xUUN3ME2wMlM{PTFizszN MWTTRW5ITVJ?
J-RT3-T3-5 NHLDe5pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIPVSJhKSzVyPUCuN|M4OTZizszN NHT4ZWZUSU6JRWK=
MOLT-13 M1XsWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmWzTWM2OD1yLkOzPFEh|ryP NFPmWlJUSU6JRWK=
SR MlnnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NI\HW|VKSzVyPUCuN|QzPjFizszN NVTZN5V4W0GQR1XS
CMK MlLvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGXHUlBKSzVyPUCuN|U4OjdizszN MnnSV2FPT0WU
ES8 Mk\2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M33QfmlEPTB;MD6zOlAzOiEQvF2= M2L2cXNCVkeHUh?=
LB647-SCLC NFjIbmtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXHJR|UxRTBwM{[3N{DPxE1? NXXHNGF7W0GQR1XS
TE-8 NH3tRlJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlTHTWM2OD1yLkO2PVM2KM7:TR?= NEj4[GNUSU6JRWK=
BV-173 NV62XFl1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXPyPGJvUUN3ME2wMlM4OTJzIN88US=> MV\TRW5ITVJ?
DEL MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUThOlBIUUN3ME2wMlM4PDh5IN88US=> NYPDXpNMW0GQR1XS
ARH-77 NUHPXJdyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFS1ZXpKSzVyPUCuN|gyQTNizszN NHf1doFUSU6JRWK=
NCCIT NWizPYJGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlXBTWM2OD1yLkO4OlQ6KM7:TR?= NUPTU4Q1W0GQR1XS
RPMI-8402 NH:3[m9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFfBc3NKSzVyPUCuN|g4ODFizszN NFrWdGxUSU6JRWK=
MONO-MAC-6 M1jnNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYHJR|UxRTBwM{i3O|Yh|ryP MmG1V2FPT0WU
SK-MM-2 M3fDXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWjrU41XUUN3ME2wMlM6QDZ6IN88US=> MmPjV2FPT0WU
CHP-126 NVXWPZliT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWfJR|UxRTBwNECyN|Eh|ryP MnjDV2FPT0WU
A101D NFXLboZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEPWdIZKSzVyPUCuOFA{KM7:TR?= MYrTRW5ITVJ?
SCH MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX7GOZFCUUN3ME2wMlQxOzR{IN88US=> MYjTRW5ITVJ?
NMC-G1 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF3mVHJKSzVyPUCuOFA{PjdizszN NH3POmxUSU6JRWK=
NCI-H209 NUDZRYlQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVLWRnpTUUN3ME2wMlQxPjF|IN88US=> MV\TRW5ITVJ?
MOLT-16 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGrEfnJKSzVyPUCuOFExOTdizszN NU\je4t{W0GQR1XS
RPMI-6666 MmDpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3LHRWlEPTB;MD60NVEzKM7:TR?= NYnoTldkW0GQR1XS
OPM-2 M3XQeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXLqSZYxUUN3ME2wMlQyPTF|IN88US=> M4Wx[HNCVkeHUh?=
MRK-nu-1 NWPMdIJRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnnQTWM2OD1yLkSzNVU{KM7:TR?= NUXlcVVHW0GQR1XS
BC-1 NIe1Z|BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MojFTWM2OD1yLkSzOFA{KM7:TR?= NVe3dlByW0GQR1XS
MHH-NB-11 NULoRoR{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXjJR|UxRTBwNEO0OVMh|ryP MX3TRW5ITVJ?
Ramos-2G6-4C10 NHjGb5ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFjrcWNKSzVyPUCuOFM5QTdizszN NG\WVGJUSU6JRWK=
LS-513 NGXGUo1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkfKTWM2OD1yLkS0OVAyKM7:TR?= M17YNnNCVkeHUh?=
K5 M3LxeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1[wRmlEPTB;MD60O|AzPSEQvF2= NYfVT5lMW0GQR1XS
HOP-62 MlexS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3\0TmlEPTB;MD60PFM2QCEQvF2= MnnKV2FPT0WU
NCI-H187 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4LJRWlEPTB;MD60PVIzPyEQvF2= MYHTRW5ITVJ?
BE-13 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXTzfYRYUUN3ME2wMlQ6PjZzIN88US=> NUnl[pVpW0GQR1XS
HC-1 NIf3RZNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NU[0XlA3UUN3ME2wMlUxPDd|IN88US=> M17STHNCVkeHUh?=
ACN MnXsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFzKbnpKSzVyPUCuOVExOjhizszN NIrNNWFUSU6JRWK=
HCC1599 M4\VV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUPJR|UxRTBwNUG1O{DPxE1? NYTVSlg4W0GQR1XS
MV-4-11 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoTFTWM2OD1yLkWzNFQyKM7:TR?= M3\2[nNCVkeHUh?=
LC-2-ad MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV\JR|UxRTBwNUO2OlMh|ryP NYrpfFFLW0GQR1XS
HL-60 NV3GW|E2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYjJR|UxRTBwNUSyOlEh|ryP NV7rdVJrW0GQR1XS
NB17 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX\kcZRnUUN3ME2wMlU1OzhizszN NXfYdnV1W0GQR1XS
TE-1 NXjLU4hrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH3JbJhKSzVyPUCuOVU{ODZizszN NHqxOoRUSU6JRWK=
NCI-H524 M{nq[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3LrdGlEPTB;MD61OVQxOSEQvF2= NXnRXW5qW0GQR1XS
MZ7-mel MnHvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIXmRWtKSzVyPUCuOVYyODVizszN MmDzV2FPT0WU
L-363 MlvjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmLLTWM2OD1yLkW2OlU4KM7:TR?= MUjTRW5ITVJ?
BL-41 M{joXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mof3TWM2OD1yLkW2PFg6KM7:TR?= MljwV2FPT0WU
LU-134-A MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NG\UNJNKSzVyPUCuOVcxPzNizszN NE\iS5pUSU6JRWK=
SIG-M5 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3LabWlEPTB;MD61O|g1QCEQvF2= MVnTRW5ITVJ?
ONS-76 M2\n[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3\HS2lEPTB;MD61PFI1OiEQvF2= NVHQU49sW0GQR1XS
KARPAS-299 NXfEUlViT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH3V[45KSzVyPUCuOVg2ODRizszN NHWzRXdUSU6JRWK=
DU-4475 MlzZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVLJR|UxRTBwNUi3NFMh|ryP MlLWV2FPT0WU
NB69 NWWzV4F[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmLXTWM2OD1yLkW5PFI2KM7:TR?= NEDkfWZUSU6JRWK=
MHH-PREB-1 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1;CXGlEPTB;MD62NFcyQSEQvF2= NGH2epFUSU6JRWK=
LU-165 MknSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2TGU2lEPTB;MD62NVgyOiEQvF2= NWe1bXFZW0GQR1XS
LOUCY MnG2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXTJR|UxRTBwNkOzOlQh|ryP Ml32V2FPT0WU
NCI-H526 NGDQNoVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{i1[WlEPTB;MD62N|U1OSEQvF2= MkjBV2FPT0WU
KE-37 NEf4doxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYDQd|V7UUN3ME2wMlY1Ojd4IN88US=> MoDpV2FPT0WU
NALM-6 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXzRNVRoUUN3ME2wMlY1QDZizszN NGjTWIpUSU6JRWK=
CW-2 NISxOnFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFi1NGFKSzVyPUCuOlU4QTRizszN Mkn5V2FPT0WU
SU-DHL-1 M1;zcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWjJR|UxRTBwNkW5OFch|ryP NYDwNJpJW0GQR1XS
NB13 M4DFSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MknyTWM2OD1yLk[2PFE4KM7:TR?= NXfCc3dpW0GQR1XS
QIMR-WIL NW\zNnRqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MojCTWM2OD1yLk[4N|Q{KM7:TR?= MmT5V2FPT0WU
ECC12 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVnrPW43UUN3ME2wMlcxODh4IN88US=> MofvV2FPT0WU
KALS-1 MojDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVPJR|UxRTBwN{C0PVIh|ryP NFjDN|dUSU6JRWK=
COR-L279 M2P2bWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGnpNmJKSzVyPUCuO|A6QTZizszN MmHXV2FPT0WU
NB14 M3jnXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnjDTWM2OD1yLkeyOlE4KM7:TR?= MojwV2FPT0WU
CCRF-CEM Mmf6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2\VN2lEPTB;MD63OFY3OSEQvF2= NHqyd5NUSU6JRWK=
SW954 M{m2fmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NE\scY5KSzVyPUCuO|U6QTlizszN NFLqdlhUSU6JRWK=
IST-SL1 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXu4RZVQUUN3ME2wMlc4OzR6IN88US=> NEDscmhUSU6JRWK=
LAMA-84 Mk[1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlPCTWM2OD1yLke3OVY4KM7:TR?= MULTRW5ITVJ?
Daudi MlqwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXTCd|hWUUN3ME2wMlc4PjhzIN88US=> M4XoenNCVkeHUh?=
BC-3 MmDES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVnJR|UxRTBwN{izNFgh|ryP NWXEc2diW0GQR1XS
HCC2998 MmL0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MW\JR|UxRTBwN{izOkDPxE1? NFrNb4xUSU6JRWK=
NCI-H69 NV7nU2FYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M33DcmlEPTB;MD64NFE1PyEQvF2= MlH4V2FPT0WU
CPC-N NWTHVW1QT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1K5eWlEPTB;MD64NFUzPCEQvF2= NWfIeXBMW0GQR1XS
NOMO-1 M3qyWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYjMRWpYUUN3ME2wMlgyODh2IN88US=> NUX2c4c5W0GQR1XS
CESS NE\Cb3ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVLJR|UxRTBwOEGxPVch|ryP M1rrS3NCVkeHUh?=
LC4-1 NFXBfZVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVP5dYVvUUN3ME2wMlg1ODB5IN88US=> NF3wPXlUSU6JRWK=
BL-70 M376[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGPVfIVKSzVyPUCuPFU4ODJizszN MV7TRW5ITVJ?
ES4 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIDuUoVKSzVyPUCuPFU5PjhizszN M4f3NHNCVkeHUh?=
HCE-T Mmm2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MU\JR|UxRTBwOEexO|Eh|ryP M1X1bXNCVkeHUh?=
JAR NUDkOphkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3\lVmlEPTB;MD64O|gzPyEQvF2= MVjTRW5ITVJ?
ST486 NX;HfFdLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MofQTWM2OD1yLki3PVE4KM7:TR?= NGi5SXlUSU6JRWK=
KS-1 NVLKZVQ{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXHJR|UxRTBwOEiwPVYh|ryP NWO5W5p5W0GQR1XS
GDM-1 NWrBSG9{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYjJR|UxRTBwOEi2PFch|ryP MVTTRW5ITVJ?
EHEB M{PN[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIH4c2tKSzVyPUCuPVI2QDVizszN NW\YRms1W0GQR1XS
LB2518-MEL MmXqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{nkSmlEPTB;MD65N|I5PCEQvF2= MXLTRW5ITVJ?
GOTO MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mor5TWM2OD1yLkm1NFc3KM7:TR?= M2rxcHNCVkeHUh?=
LXF-289 MoS2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{DJNWlEPTB;MD65OVkxOSEQvF2= MlzkV2FPT0WU
ES6 MkPjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV;JR|UxRTBwOU[0N|ch|ryP M2m4dXNCVkeHUh?=
OS-RC-2 NX\QdppFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NU\zcJJUUUN3ME2wMlk3QDNizszN M12wZnNCVkeHUh?=
DMS-153 Mk\2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUHTNlFmUUN3ME2wMlk4PDZ7IN88US=> NGmyWXZUSU6JRWK=
SK-PN-DW M4rFZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEfpWGtKSzVyPUCuPVc5OzFizszN MmTjV2FPT0WU
HH MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVvkboJMUUN3ME2wMlk5QTV7IN88US=> NELSU4lUSU6JRWK=
SH-4 Mlr1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1fkbWlEPTB;MT6wNlQyKM7:TR?= NUjQO2FmW0GQR1XS
MOLT-4 M2PTSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2HGSGlEPTB;MT6wN|Q2PCEQvF2= M{jQU3NCVkeHUh?=
TGW NH\IWXRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NELV[JZKSzVyPUGuNFc3PzVizszN NVLFRlZHW0GQR1XS
L-540 NWnkUpVQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmrCTWM2OD1zLkGwOlA1KM7:TR?= MlrsV2FPT0WU
PF-382 Mk\aS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4i2OmlEPTB;MT6xNVUyOyEQvF2= NWTwU2I2W0GQR1XS
LC-1F MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{XvNGlEPTB;MT6xNlAxPyEQvF2= NH;5UGNUSU6JRWK=
OVCAR-4 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV7CeWtNUUN3ME2xMlE{OTZ3IN88US=> NGXCbFFUSU6JRWK=
A4-Fuk NYH0WpY4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVnJR|UxRTFwMUWzOlQh|ryP NYrEbnR7W0GQR1XS
HCC2218 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnTxTWM2OD1zLkG2OlQyKM7:TR?= MnfrV2FPT0WU
HAL-01 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH33eGJKSzVyPUGuNVY6PDNizszN NYTTV4h1W0GQR1XS
IST-MEL1 MnzOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmK0TWM2OD1zLkG3OlU6KM7:TR?= NIPBbIhUSU6JRWK=
NCI-H719 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MojmTWM2OD1zLkG3PFk5KM7:TR?= M1XqOHNCVkeHUh?=
EVSA-T MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mm\wTWM2OD1zLkG4NVE1KM7:TR?= NFH4dVlUSU6JRWK=
SK-NEP-1 MnjnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYDJR|UxRTFwMkCyOlYh|ryP NX20eYt6W0GQR1XS
OCUB-M NECwVItIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXnQbZBZUUN3ME2xMlIyPDh7IN88US=> MnjGV2FPT0WU
MEG-01 NULOdHFVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYfJR|UxRTFwMkKxNVgh|ryP MkXTV2FPT0WU
no-10 NF;pZVNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlvJTWM2OD1zLkKzNVEzKM7:TR?= MWjTRW5ITVJ?
MHH-CALL-2 NU\SfoVOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1;LPWlEPTB;MT6yOFczOSEQvF2= NVvTRZRRW0GQR1XS
SK-N-DZ NXewOYpFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mk\2TWM2OD1zLkK0O|c3KM7:TR?= MonWV2FPT0WU
SCLC-21H NVTGR|ZtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVLJR|UxRTFwMk[0O|gh|ryP Mn3UV2FPT0WU
CTV-1 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHzmbIFKSzVyPUGuNlc1OjVizszN NU\kXY5uW0GQR1XS
NB1 Ml3jS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVjJR|UxRTFwMke3N|Ih|ryP MXjTRW5ITVJ?
NCI-H64 NYjzO4xST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmHoTWM2OD1zLkK4OFYzKM7:TR?= MlnUV2FPT0WU
MDA-MB-134-VI NHLLZpdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV3JR|UxRTFwMki1O|ch|ryP NF23OlNUSU6JRWK=
LB2241-RCC NGC5O2ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnjWTWM2OD1zLkK4OlY{KM7:TR?= MV3TRW5ITVJ?
8-MG-BA MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmXWTWM2OD1zLkK4PFY3KM7:TR?= NELufVVUSU6JRWK=
LP-1 NYDINXZNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFrxUpNKSzVyPUGuNlk6PDdizszN NV;pUm5rW0GQR1XS
LS-411N MnvaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWK0XFdkUUN3ME2xMlMxQTl6IN88US=> NI\lW5JUSU6JRWK=
CAL-148 M1fET2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX3neldtUUN3ME2xMlMzPTR{IN88US=> NU\ZWIF5W0GQR1XS
NCI-H2171 Mnj0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYjBO4UyUUN3ME2xMlM1PTB{IN88US=> MkCzV2FPT0WU
JiyoyeP-2003 NF3Y[pNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2PqOWlEPTB;MT6zOVM6KM7:TR?= NFL2WW5USU6JRWK=
NCI-H2107 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{jPfWlEPTB;MT6zOVg5OyEQvF2= NVTEblRvW0GQR1XS
BB30-HNC MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH20[mtKSzVyPUGuN|g6PzhizszN MlS5V2FPT0WU
K-562 NHu5S4tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NITGZmdKSzVyPUGuN|kzOTlizszN MXjTRW5ITVJ?
PSN1 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmXLTWM2OD1zLkSyNlg4KM7:TR?= M3;IdXNCVkeHUh?=
HCC2157 M3y0cGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3;4VmlEPTB;MT60NlY6OSEQvF2= NEfPXYtUSU6JRWK=
SBC-1 NH\YSYtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUe4NWVZUUN3ME2xMlQzPzRzIN88US=> MVfTRW5ITVJ?
MC116 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlLYTWM2OD1zLkSzOlE2KM7:TR?= MoDpV2FPT0WU
KARPAS-422 M4nLZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkjBTWM2OD1zLkS1N|U5KM7:TR?= NIjhWXdUSU6JRWK=
LB996-RCC MnSzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUfrW4p[UUN3ME2xMlQ4OTB|IN88US=> MlW4V2FPT0WU
MSTO-211H MknsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2rINmlEPTB;MT60O|k5PyEQvF2= MmT6V2FPT0WU
BT-474 NUO0Rml5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUnLU|FKUUN3ME2xMlUyPzZ2IN88US=> NIDiRWNUSU6JRWK=
A388 MmPDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXywNZhWUUN3ME2xMlUyQTR3IN88US=> Mn;RV2FPT0WU
SJSA-1 NFH4TpVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3nlV2lEPTB;MT61NlI3KM7:TR?= M1jObnNCVkeHUh?=
COLO-829 NVjZTFNWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHm5XlVKSzVyPUGuOVM2PjRizszN M2nWenNCVkeHUh?=
KM-H2 NGLFSVZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4DTXWlEPTB;MT61OlY4KM7:TR?= MkDhV2FPT0WU
GR-ST MlfJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MULJR|UxRTFwNU[4NkDPxE1? NWfjXVdoW0GQR1XS
RPMI-8866 NGfwb3hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlzvTWM2OD1zLk[wNVQ1KM7:TR?= M{Pq[HNCVkeHUh?=
KG-1 NIXVVI9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX7JR|UxRTFwNkG5NFEh|ryP NH:0OXFUSU6JRWK=
NCI-H82 MkS5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIfYbplKSzVyPUGuOlM1ODZizszN NEfaeGRUSU6JRWK=
LB1047-RCC NIrqXWtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3vZdWlEPTB;MT62N|Q2QSEQvF2= NVP5boRnW0GQR1XS
KM12 M{LMXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MljLTWM2OD1zLk[0O{DPxE1? MmTiV2FPT0WU
NB5 Mm\hS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1S1b2lEPTB;MT62OVY4PyEQvF2= MUHTRW5ITVJ?
HDLM-2 MoK5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXrJR|UxRTFwNkiyPFEh|ryP Mlv3V2FPT0WU
KU812 NFe2SnZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{nlV2lEPTB;MT62PVYxPSEQvF2= NYPHPWJwW0GQR1XS
DB NYXzW|JiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml3nTWM2OD1zLkewN|U{KM7:TR?= Mo\FV2FPT0WU
HD-MY-Z MmSwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{LJTWlEPTB;MT63OVI{PCEQvF2= MYnTRW5ITVJ?
KURAMOCHI NHrzbolIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1rVZWlEPTB;MT63O|IxPyEQvF2= M3zmSnNCVkeHUh?=
ETK-1 MkjtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2jU[GlEPTB;MT63PFg4QSEQvF2= MV\TRW5ITVJ?
SK-UT-1 NWnCNpBvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYXJR|UxRTFwN{mzPFgh|ryP NV;oelNEW0GQR1XS
HUTU-80 MnvhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmHQTWM2OD1zLke5OVA5KM7:TR?= MnLIV2FPT0WU
ES7 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3nTR2lEPTB;MT64NFMxOiEQvF2= MWDTRW5ITVJ?
SW872 NF3WOWhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3HpRWlEPTB;MT64NVM6PSEQvF2= Mmn6V2FPT0WU
TK10 NXT0SIZ5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWfJR|UxRTFwOEOxNFgh|ryP MXvTRW5ITVJ?
LB831-BLC NI\FRZZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlzFTWM2OD1zLkizOVY{KM7:TR?= NXvqc|g1W0GQR1XS
TE-9 M2PZfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkewTWM2OD1zLki0OFIzKM7:TR?= MW\TRW5ITVJ?
MLMA M33McGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVHJR|UxRTFwOEiyN|Qh|ryP MYrTRW5ITVJ?
D-542MG M3jNbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4\1TGlEPTB;MT64PVM4OyEQvF2= MoPpV2FPT0WU
EW-16 NVvDTVFpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2HOPWlEPTB;MT65NlczKM7:TR?= NWiwO49LW0GQR1XS
LOXIMVI MoXOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{PiPWlEPTB;MT65N|I5KM7:TR?= NGD3XZBUSU6JRWK=
GB-1 MmTlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{nITGlEPTB;MT65N|g3PiEQvF2= M4G4VXNCVkeHUh?=
IST-SL2 NFvlN2pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NU\kSVRqUUN3ME2yMlAxOjZ{IN88US=> NEC0RlFUSU6JRWK=
LAN-6 Mo\TS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2\TSGlEPTB;Mj6wNVk3PiEQvF2= NYH4N3VIW0GQR1XS
NCI-H510A NV;XRodWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NG\wbm5KSzVyPUKuNFQ2ODJizszN NGTB[IJUSU6JRWK=
NCI-H1092 NV;GbXFZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFjSNmtKSzVyPUKuNFUyOjRizszN M1XacnNCVkeHUh?=
HT MnrxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXzBOZZrUUN3ME2yMlExPDV2IN88US=> NVLqO4ZqW0GQR1XS
RL95-2 NEjwd4ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{fZU2lEPTB;Mj6xNVQ5OiEQvF2= M2HyNHNCVkeHUh?=
NCI-H1355 NFjWbIZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXrxe2VDUUN3ME2yMlEyPzl{IN88US=> M2rYZnNCVkeHUh?=
NCI-H720 NVLBVpc2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUHJR|UxRTJwMU[4O|Mh|ryP MkizV2FPT0WU
NCI-H1522 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYfJR|UxRTJwMkG3NlMh|ryP MkTPV2FPT0WU
LB373-MEL-D NETWbpVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHLyUINKSzVyPUKuNlY6ODJizszN MXvTRW5ITVJ?
DG-75 NF:4blVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3nmS2lEPTB;Mj6yO|E1QCEQvF2= MXPTRW5ITVJ?
ML-2 NVvucItTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGfJZZJKSzVyPUKuN|I5PTVizszN M3zmXnNCVkeHUh?=
SF126 M{\Le2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkG0TWM2OD1{LkOzNFk1KM7:TR?= MUnTRW5ITVJ?
MPP-89 NUXaNm9lT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmPzTWM2OD1{LkOzNVQ2KM7:TR?= Mo\iV2FPT0WU
NCI-H345 M2fkUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEnifW5KSzVyPUKuN|MzPzdizszN MXjTRW5ITVJ?
LS-123 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVnJR|UxRTJwM{S5N|Yh|ryP MX3TRW5ITVJ?
NB10 NFPJcIpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIDkSnVKSzVyPUKuOFExQTJizszN M1LxdHNCVkeHUh?=
CGTH-W-1 NYPNc205T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUj5TXYxUUN3ME2yMlQzOjZ5IN88US=> NEDjUnJUSU6JRWK=
CP66-MEL NGjlW2ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NW[5PII3UUN3ME2yMlQ4PzdizszN M{fWc3NCVkeHUh?=
L-428 MoLkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn2wTWM2OD1{LkS4OVIyKM7:TR?= M1;PeHNCVkeHUh?=
DMS-79 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4K4XWlEPTB;Mj61OFExOyEQvF2= M3PBeHNCVkeHUh?=
NCI-H1882 NH\QVYlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV;wc45FUUN3ME2yMlY4PTZ{IN88US=> MUnTRW5ITVJ?
KGN MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXXJR|UxRTJwN{[4O|Yh|ryP M3HTUHNCVkeHUh?=
EW-1 NIj2d25Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2jRb2lEPTB;Mj63O|A5OyEQvF2= MUXTRW5ITVJ?
U-266 MlW4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVzlS3hoUUN3ME2yMlg1QDJ|IN88US=> MUfTRW5ITVJ?
COLO-320-HSR MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3mwPGlEPTB;Mj64OVY1OSEQvF2= NIPRXIhUSU6JRWK=
KMOE-2 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{jpW2lEPTB;Mj64O|cyOSEQvF2= NWPGWIlqW0GQR1XS
BB49-HNC NHXDbIlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlvsTWM2OD1{LkmyOFgh|ryP MnnkV2FPT0WU
GI-1 NUfxZY1CT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXjJR|UxRTJwOUK5OVch|ryP NI\xcYpUSU6JRWK=
NCI-H1304 NHfyc3FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NW\mXIRZUUN3ME2zMlAxPTFzIN88US=> M2C2fnNCVkeHUh?=
NCI-H2227 NELQUoFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYnJR|UxRTNwMEKwO|kh|ryP M4C2XHNCVkeHUh?=
U-87-MG MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkPzTWM2OD1|LkCzOVE{KM7:TR?= MXjTRW5ITVJ?
NCI-H747 M1fCRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFPOcJJKSzVyPUOuNFUzODZizszN MWrTRW5ITVJ?
CTB-1 M3;zfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYD6PYNSUUN3ME2zMlA2Ozd4IN88US=> MlrVV2FPT0WU
RPMI-8226 M4j3Xmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoPOTWM2OD1|LkG0N|c5KM7:TR?= M3fjZ3NCVkeHUh?=
NCI-H2141 M1HyNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkTCTWM2OD1|LkG2OVY3KM7:TR?= NYfKR|FpW0GQR1XS
IST-MES1 M4LYSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn35TWM2OD1|LkG4Nlc6KM7:TR?= MonZV2FPT0WU
TE-5 NFfzeVZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXvWVJhJUUN3ME2zMlIyOzR{IN88US=> NVTpU4hGW0GQR1XS
UACC-257 NUjI[HduT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1j1VGlEPTB;Mz60N|Y2QSEQvF2= M2XJRXNCVkeHUh?=
SK-N-FI MoPHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFPZNmxKSzVyPUOuOFUzOjdizszN MYnTRW5ITVJ?
MFH-ino NVzsb5JWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4\4VmlEPTB;Mz60OlU5QSEQvF2= NVzncXlWW0GQR1XS
SF268 NEH6UHZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NI\kbnpKSzVyPUOuOFgyPzRizszN M33ER3NCVkeHUh?=
TE-12 MmWwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGXrUGZKSzVyPUOuOVE3QTlizszN NVrSWHg6W0GQR1XS
NB6 NXHWbXNlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlezTWM2OD1|LkW1OVY{KM7:TR?= MkXkV2FPT0WU
DJM-1 NFvqWI5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MonETWM2OD1|LkW5PFk6KM7:TR?= NV7QUGluW0GQR1XS
MZ1-PC MoDNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4raS2lEPTB;Mz62NVYzPCEQvF2= MUPTRW5ITVJ?
OCI-AML2 M4rLPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWnJR|UxRTNwNkK2O|Eh|ryP MYfTRW5ITVJ?
NCI-H1155 Mn\NS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXHJR|UxRTNwN{C5OFch|ryP NVXQdIc5W0GQR1XS
RKO MmjJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mnm5TWM2OD1|Lke3NVg6KM7:TR?= NXi2[Il{W0GQR1XS
ECC4 NVTMdoEyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2XDcWlEPTB;Mz65O|E6PSEQvF2= NV;R[XFRW0GQR1XS
BB65-RCC M2HKO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWTxZm83UUN3ME2zMlk4PTR5IN88US=> NUfiO3Q3W0GQR1XS
EB-3 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVzzUoRzUUN3ME2zMlk6PjN|IN88US=> MkHCV2FPT0WU
SHP-77 NHu5d3FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYnJR|UxRTRwMEC1NlQh|ryP MnTmV2FPT0WU
NCI-H2196 Ml7SS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHfhXnVKSzVyPUSuNFU3OjVizszN MnnyV2FPT0WU
GI-ME-N MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXzJR|UxRTRwME[zPVkh|ryP MWnTRW5ITVJ?
MN-60 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEfTT5ZKSzVyPUSuNVA5PyEQvF2= MXrTRW5ITVJ?
NCI-H1694 NE\r[VlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1PsSmlEPTB;ND6xN|QxPSEQvF2= M2q0Z3NCVkeHUh?=
LU-65 NGDGN4ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NES1OG5KSzVyPUSuNVU{OzJizszN M4TY[HNCVkeHUh?=
NCI-H1436 NUjjVYs1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnXMTWM2OD12LkG4N|M{KM7:TR?= NYK4[GxnW0GQR1XS
KINGS-1 M4X1emdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYDTXlN[UUN3ME20MlMyPDN{IN88US=> MonQV2FPT0WU
GT3TKB M3Xrfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV3JR|UxRTRwM{OyOlgh|ryP M1TETXNCVkeHUh?=
Becker MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXXJR|UxRTRwM{ezNVIh|ryP NY[zeIE5W0GQR1XS
HCC1187 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3zB[GlEPTB;ND64PVY2PyEQvF2= MnrVV2FPT0WU
D-502MG M3rVbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFruSmpKSzVyPUWuNFA1OTZizszN M{HqWnNCVkeHUh?=
VA-ES-BJ MlXMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml6zTWM2OD13LkGzO|c5KM7:TR?= NF;tOm1USU6JRWK=
NB7 NHTQUWxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUDJR|UxRTVwMUSxNVIh|ryP MYnTRW5ITVJ?
SW962 NEDIN25Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH\1VnJKSzVyPUWuN|g5OTRizszN NFLIOnFUSU6JRWK=
no-11 NGXib5NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGjYTWFKSzVyPUWuO|Y{PDNizszN NHXiblZUSU6JRWK=
KNS-81-FD NXzPeIhZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3LNbGlEPTB;NT65NFY6PCEQvF2= NWDqOHpUW0GQR1XS
COLO-684 M2LDOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MY\JR|UxRTVwOUm0PVQh|ryP M4fDO3NCVkeHUh?=
D-263MG MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3jRSGlEPTB;Nj6wPFg6PSEQvF2= M4DFdXNCVkeHUh?=
EW-24 MlvIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{W0VWlEPTB;Nj6yPFUyKM7:TR?= NVW3NXdmW0GQR1XS
TE-10 M1mxVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVLJR|UxRTZwNEK2NlMh|ryP MlvyV2FPT0WU
EKVX NEG0dJFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUe1ZWFmUUN3ME22MlQ3OzJzIN88US=> Mk[5V2FPT0WU
NCI-H1648 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1LmUGlEPTB;Nj62O|U2PyEQvF2= M3\EOHNCVkeHUh?=
LB771-HNC M2\lUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIPYZW1KSzVyPU[uPVI{ODFizszN NGOxeo9USU6JRWK=
SK-MEL-1 NIr0VYdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn[wTWM2OD16LkGzNVY3KM7:TR?= MVjTRW5ITVJ?
COLO-668 NF7NdmVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVfJR|UxRThwMke3PFYh|ryP NF\l[3hUSU6JRWK=
EW-12 MoCzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2job2lEPTB;OD60NFgxOyEQvF2= NXTwPG5VW0GQR1XS
A253 MonoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkLnTWM2OD16Lki0OlYyKM7:TR?= NGfES3ZUSU6JRWK=
NCI-H2126 NG\FZWJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NE\6VWlKSzVyPUiuPFk{OTlizszN NY\XWm1zW0GQR1XS
Calu-6 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mli3TWM2OD16Lkm5NFQzKM7:TR?= NHLTeHRUSU6JRWK=
NCI-H23 NXHHbY9QT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlrwTWM2OD17LkG3O|Q3KM7:TR?= M3TlenNCVkeHUh?=
WSU-NHL MkjTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUP0XINXUUN3ME25Mlc4PDd6IN88US=> MkTwV2FPT0WU
MMAC-SF M4P3bWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoPYTWM2OD17Lkm3PVA1KM7:TR?= M3XuNnNCVkeHUh?=
SK-LMS-1 MkTpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3niZWlEPTB;MUCuNlg{PCEQvF2= NILEXXZUSU6JRWK=
GCIY MmjFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVLyXYdYUUN3ME2xNE42QTJ2IN88US=> M1LoPXNCVkeHUh?=
TE-15 NVrGbJlkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGjwdXJKSzVyPUGxMlYxODRizszN NVXoW2FJW0GQR1XS
EoL-1-cell MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV\VNJpGUUN3ME2xNU44Pjh{IN88US=> Mlj0V2FPT0WU
NCI-H2081 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnTVTWM2OD1zMT63O|g3KM7:TR?= NVz1Xo5uW0GQR1XS
EW-3 Ml\hS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGLHSoxKSzVyPUGyMlI1PjNizszN NWTE[2t{W0GQR1XS
CAS-1 NEXvepBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3;GUmlEPTB;MUKuN|Y{OSEQvF2= MV\TRW5ITVJ?
C2BBe1 M1TDd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEDESHBKSzVyPUGyMlYyOzFizszN MUDTRW5ITVJ?
D-247MG MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlrZTWM2OD1zMj63PVUzKM7:TR?= NWXvTZR[W0GQR1XS
NCI-SNU-5 NFjUS|ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYnJR|UxRTF{LkiwNVMh|ryP NUnrTW5pW0GQR1XS
LS-1034 NIHnTFZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXLZTmJHUUN3ME2xOE4{QTd3IN88US=> MlnmV2FPT0WU
EW-18 MlH2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXzvdlByUUN3ME2xOE41PDhizszN NYLTPYg1W0GQR1XS
Raji NX\ifGt[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVHJR|UxRTF2LkWwOFkh|ryP MmLWV2FPT0WU
D-283MED MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVvJR|UxRTF2Lk[yO|Eh|ryP M2PPOXNCVkeHUh?=
MZ2-MEL NXHvZYFbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV7q[o5uUUN3ME2xOE46Pjl4IN88US=> MUfTRW5ITVJ?
NCI-SNU-16 M3Hkb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYrJR|UxRTF3LkS2N|Mh|ryP NW\UWYQ{W0GQR1XS
P30-OHK M161UWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3TZ[WlEPTB;MUeuO|g{OSEQvF2= MUfTRW5ITVJ?
RXF393 NHnEOnhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVvJR|UxRTF7LkCxPFYh|ryP MlPMV2FPT0WU
NCI-H1395 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGXvWmVKSzVyPUKwMlY4ODNizszN Mk\nV2FPT0WU
U-698-M MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUfJR|UxRTJyLkewO|Uh|ryP NGHKcpdUSU6JRWK=
NCI-SNU-1 NWT3U2JoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVLJR|UxRTJyLkeyNlMh|ryP M2nkSXNCVkeHUh?=
SW684 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmK4TWM2OD1{MT6xO|E3KM7:TR?= M1jmN3NCVkeHUh?=
NCI-H716 M{LieWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MljYTWM2OD1{MT6zNVU1KM7:TR?= MU\TRW5ITVJ?
JVM-2 NH;qd4pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{i2eWlEPTB;MkGuOFE{OyEQvF2= NIjNWmxUSU6JRWK=
NCI-H1581 NWPX[m1kT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF\SOXBKSzVyPUKyMlQyPDhizszN M1PIUnNCVkeHUh?=
CA46 NEXDb4lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlrRTWM2OD1|MT62PVM3KM7:TR?= Ml3tV2FPT0WU
SNB75 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYnqXXNZUUN3ME2zN{43PTB|IN88US=> MmDWV2FPT0WU
KNS-42 M1u4T2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1O5dmlEPTB;M{WuPVYzPCEQvF2= NGXEfI1USU6JRWK=
TUR NUTpNmJ6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoHqTWM2OD1|Nj6wOVIyKM7:TR?= MYfTRW5ITVJ?
REH MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVzJR|UxRTN5LkiyNVEh|ryP NEi3[pNUSU6JRWK=
EW-22 NF\pPJhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUTJR|UxRTR{LkK4PFUh|ryP NXS1[2p[W0GQR1XS
NCI-H446 NV71Xpc{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVfzZYZ6UUN3ME20Nk44QDV|IN88US=> M17OVHNCVkeHUh?=
ES3 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnywTWM2OD12Mz6xN|M6KM7:TR?= MVrTRW5ITVJ?
EW-11 NGnLT|ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoLmTWM2OD12ND64NlE5KM7:TR?= MXrTRW5ITVJ?
RH-1 M4PR[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml3GTWM2OD12Nz61PFEzKM7:TR?= MYjTRW5ITVJ?

... Click to View More Cell Line Experimental Data

In vivo MS-275 exhibits great antitumor activity against human tumor xenografts except HCT-15 at 49 mg/kg. [1] MS-275 demonstrates promising therapeutic potential in both solid and hematologic malignancies, as well as regulation of physiologic and aberrant gene expression. [4] MS-275, combination with IL-2, has great antitumor activity to renal cell carcinoma xenograft model, which due to decreased T regulatory cells and increased splenocytes. [5]

Protocol

Kinase Assay:

[6]

+ Expand

Standard HDAC Assays:

Rat liver enzyme is diluted 1:6 with HDAC buffer. Recombinant human HDACs are diluted 1:4 in HDAC buffer. For standard HDAC assays, 60 μL of HDAC buffer is mixed with 10 μL of diluted enzyme solution at 30 °C. The HDAC reaction is started by adding 30 μL substrate solution in HDAC buffer followed by 30 min of incubation at 30 °C. The reaction is stopped by adding 100 μL trypsin solutions (10 mg/ml trypsin in 50 mM Tris-HCl [pH 8.0], 100 mM NaCl, 2 μM TSA). After a 20 min incubation period at 30 °C, the release of AMC is monitored by measuring the fluorescence at 460 nm (λex = 390 nm). Fluorescence intensity is calibrated using free AMC. For standard time course experiments, 20 pmol of substrate is used in the initial 100 μL HDAC reaction. Km and Vmax values are determined by measuring the fluorescence AMC generated by enzymatic cleavage of 2–50 pmol of substrate. The experimental data are analyzed using a Hanes plot. The AMC signals are recorded against a blank with buffer and substrate but without the enzyme.
Cell Research:

[2]

+ Expand
  • Cell lines: A2780, Calu-3, HL-60, K562, St-4, HT-29, KB-3-1, Capan-1, 4-1St and HCT-15 cells
  • Concentrations: ~ 10 μM
  • Incubation Time: 3 days
  • Method:

    Cancer cells (5 × 103) are seeded into each well of 96-well plates and cultured with graded concentrations of MS-275 for 3 days. The cells are stained with 0.1 mg/mL neutral red for 1 hour in a CO2-incubator, and, after aspiration of the medium, OD540 of the neutral red solubilized with 50 μL of ethanol and 150 μL of 0.1 M Na2HPO4 is measured. The IC50 value is determined by plotting growth inhibition of the cells against the logarithm of the drug concentration.


    (Only for Reference)
Animal Research:

[1]

+ Expand
  • Animal Models: A2780, HT-29, HTC-15, KB-3-1, 4-1St, St-4, Capan-1 and Calu-3 cells are injected subcutaneously into the flank of nude mice.
  • Formulation: Dissolved with 0.05 N HCl, 0.1% Tween 80
  • Dosages: 12.3, 24.5 and 49 mg/kg
  • Administration: Administered orally once daily 5 days per week for 4 weeks
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 75 mg/mL (199.25 mM)
Water <1 mg/mL
Ethanol <1 mg/mL
In vivo 2% DMSO+30% PEG 300 10mg/mL

* 1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 376.41
Formula

C21H20N4O3

CAS No. 209783-80-2
Storage powder
in solvent
Synonyms SNDX-275

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT03018249 Not yet recruiting Grade 1 Endometrial Endometrioid Adenocarcinoma|Grade 2 Endometrial Endometrioid Adenocarcinoma|Grade 3 Endometrial Endometrioid Adenocarcinoma|Uterine Corpus Adenosarcoma National Cancer Institute (NCI) August 2017 Phase 2
NCT02697630 Not yet recruiting Metastatic Uveal Melanoma Vastra Gotaland Region|Merck Sharp & Dohme Corp.|Syndax Pharmaceuticals March 2017 Phase 2
NCT02936752 Not yet recruiting Previously Treated Myelodysplastic Syndrome National Cancer Institute (NCI) March 2017 Phase 1
NCT03024437 Not yet recruiting Metastatic Cancer|Renal Cancer Roberto Pili|Indiana University January 2017 Phase 1|Phase 2
NCT02780804 Recruiting Childhood Brain Stem Neoplasm|Childhood Lymphoma|Childhood Solid Neoplasm|Pineal Region Neoplasm|Recurrent Childhood Central Nervous System Neoplasm|Recurrent Childhood Visual Pathway Glioma|Refractory Central Nervous System Neoplasm National Cancer Institute (NCI) December 2016 Phase 1
NCT02922933 Recruiting Volunteers|Healthy Volunteers|Human Volunteers|Normal Volunteers Syndax Pharmaceuticals November 2016 Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

HDAC Signaling Pathway Map

HDAC Inhibitors with Unique Features

Related HDAC Products

Tags: buy Entinostat (MS-275) | Entinostat (MS-275) supplier | purchase Entinostat (MS-275) | Entinostat (MS-275) cost | Entinostat (MS-275) manufacturer | order Entinostat (MS-275) | Entinostat (MS-275) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID